Oculis Reports New Phase 2 ACUITY Biomarker Data for Privosegtor

Oculis has reported new biomarker data from its Phase 2 ACUITY study for Privosegtor, indicating its ability to cross the blood-brain and blood-retina barriers. The data suggests potential neuroprotective effects for conditions like optic neuritis, showing improved visual function and maintenance of retinal anatomy. This advancement highlights Oculis's ongoing clinical progress in its ophthalmic and neuro-ophthalmic pipeline.